Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Corvus Pharmaceuticals Inc (CRVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CRVS (4-star) is a STRONG-BUY. BUY since 1 days. Profits (0.00%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.75
1 Year Target Price $15.75
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 801.12% | Avg. Invested days 27 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 361.39M USD | Price to earnings Ratio - | 1Y Target Price 15.75 |
Price to earnings Ratio - | 1Y Target Price 15.75 | ||
Volume (30-day avg) 6 | Beta 0.41 | 52 Weeks Range 2.54 - 10.00 | Updated Date 08/15/2025 |
52 Weeks Range 2.54 - 10.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.13 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.85% | Return on Equity (TTM) -68.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 288069089 | Price to Sales(TTM) - |
Enterprise Value 288069089 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.36 | Shares Outstanding 74514000 | Shares Floating 60332527 |
Shares Outstanding 74514000 | Shares Floating 60332527 | ||
Percent Insiders 3.96 | Percent Institutions 58.07 |
Upturn AI SWOT
Corvus Pharmaceuticals Inc
Company Overview
History and Background
Corvus Pharmaceuticals Inc. was founded in 2011 and is focused on developing and commercializing novel immuno-oncology therapies to significantly improve the lives of people with cancer.
Core Business Areas
- Clinical Development: Focuses on advancing its pipeline of novel immuno-oncology therapies through clinical trials.
- Research and Development: Involves identifying and developing new targets and drug candidates for cancer immunotherapy.
Leadership and Structure
The leadership team includes key executives in drug development and clinical research. The organizational structure is typical of a biotechnology company, with departments focused on R&D, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Soquelitin (CPI-818): A selective ITK inhibitor being developed for T cell lymphomas and autoimmune diseases. Currently in Phase 1b/2 clinical trial. Market share data is not yet available as it is not yet approved. Competitors include companies developing other T cell lymphoma treatments, such as Kyowa Kirin (Poteligeo) and Seattle Genetics (Adcetris).
- CPI-006: An anti-CD73 antibody designed to block the production of adenosine. Currently in Phase 1/1b clinical trial. Market share data is not yet available as it is not yet approved. Competitors include companies developing other anti-CD73 antibodies, such as AstraZeneca.
Market Dynamics
Industry Overview
The immuno-oncology industry is a rapidly growing field focused on harnessing the power of the immune system to fight cancer. It includes a wide range of therapies, including checkpoint inhibitors, cell therapies, and immunomodulatory agents.
Positioning
Corvus is positioned as an innovative immuno-oncology company with a focus on developing novel therapies targeting T cells and adenosine pathways. Its competitive advantage lies in its unique approach to modulating the immune system.
Total Addressable Market (TAM)
The TAM for immuno-oncology is estimated to be in the tens of billions of dollars and growing. Corvus is positioned to capture a share of this market with its pipeline of novel therapies.
Upturn SWOT Analysis
Strengths
- Novel immuno-oncology pipeline
- Experienced management team
- Strong intellectual property position
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on clinical trial success
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
Competitive Landscape
Corvus faces strong competition from established pharmaceutical companies in the immuno-oncology space. Its success depends on demonstrating the efficacy and safety of its novel therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing its clinical pipeline and securing funding.
Future Projections: Future growth depends on the success of its clinical trials and potential partnerships. Analyst estimates should be reviewed from financial analysis sites.
Recent Initiatives: Recent initiatives include advancing clinical trials for Soquelitin and CPI-006, and exploring new therapeutic targets.
Summary
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel immuno-oncology therapies. Their pipeline, while promising, is early stage, making the company inherently risky. Success hinges on positive clinical trial outcomes and securing partnerships. Corvus needs to carefully manage its cash burn and navigate the competitive immuno-oncology landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Corvus Pharmaceuticals Inc. website
- SEC Filings
- Analyst Reports (FactSet, Bloomberg)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and is subject to change. Investing in biotechnology companies is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corvus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-03-23 | Co-Founder, President, CEO & Chairman of the Board Dr. Richard A. Miller M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.corvuspharma.com |
Full time employees 31 | Website https://www.corvuspharma.com | ||
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.